5 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2221839/medical-products-stocks-earnings-due-on-feb-7-ste-pahc-nvst?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221839
Feb 06, 2024 - Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.
zc:-3564055900211556282
0
https://www.zacks.com/stock/news/2226352/what-makes-phibro-pahc-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2226352
Feb 14, 2024 - Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zc:-2767039145509108688
0
https://www.zacks.com/stock/news/2249713/are-investors-undervaluing-phibro-animal-health-pahc-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2249713
Apr 03, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zc:5170734917544700914
0
https://www.zacks.com/stock/news/2222992/phibro-pahc-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2222992
Feb 07, 2024 - Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:-2715959859855452498
0
https://www.zacks.com/stock/news/2237419/phibro-pahc-appears-well-poised-on-launches-vaccine-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2237419
Mar 07, 2024 - Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
zc:-7444438580819497867
0